The CLDN11 antibody targets claudin-11. a key component of tight junction proteins that regulate paracellular barrier function and cell polarity. Claudin-11. a member of the claudin family, is a transmembrane protein with four domains, critical for forming tight junction strands. It is highly expressed in myelinating cells, particularly oligodendrocytes in the central nervous system (CNS) and Schwann cells in the peripheral nervous system (PNS), where it contributes to the structural integrity of myelin sheaths. Additionally, it is found in Sertoli cells of the testes, forming the blood-testis barrier.
CLDN11 antibodies are widely used in research to study myelination, neural development, and reproductive biology. In neuropathology, they help investigate demyelinating diseases like multiple sclerosis (MS) and neurodegenerative disorders. Dysregulation of claudin-11 has also been linked to infertility and certain cancers, making its antibody a tool for exploring tumor metastasis mechanisms.
These antibodies are employed in techniques such as Western blotting, immunohistochemistry, and immunofluorescence to detect protein expression, localization, and interactions. Validation often includes knockout controls to confirm specificity. Research using CLDN11 antibodies has advanced understanding of cellular barriers, myelination defects, and potential therapeutic targets for related diseases.